CRC_Corrona PSO 500
Corrona Psoriasis Registry
The primary objective of the Corrona Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a national cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.
Key Inclusion Criteria:
1) The subject has psoriasis diagnosed by a dermatologist
2) The subject is at least 18 years of age or older (age ≥ 18 years)
3) The subject has started on or switched to a systemic psoriasis treatment within the previous 12 months. FDA-approved biologic treatments for psoriasis and non-biologic treatments(methotrexate, cyclosporine, or apremilast only) are allowed.
David Smith, M.D.
CALGB (Cancer and Leukemia Group B)